Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
Public ClinicalTrials.gov record NCT03383094. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Study identification
- NCT ID
- NCT03383094
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Loren Mell, MD
- Other
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin Drug
- Pembrolizumab Drug
- Radiation therapy Radiation
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 14, 2018
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2027
- Last update posted
- Oct 6, 2025
2018 – 2027
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| H. Lee Moffitt Cancer Center & Research Facility | Tampa | Florida | 33612 | — |
| Washington University School of Medicine, Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03383094, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2025 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03383094 live on ClinicalTrials.gov.